ACAD reports encouraging second-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.

Explore ACADIA Pharmaceuticals' Q2 2025 earnings highlights, featuring strong revenue growth, DAYBUE expansion, NUPLAZID guidance raise, and robust ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2025.

Acadia secures NUPLAZID patent protection through 2030In other recent news, Acadia Pharmaceuticals has seen significant developments impacting its financial outlook and strategic direction. Deutsche ...

Acadia secures NUPLAZID patent protection through 2030In other recent news, Acadia Pharmaceuticals has seen significant developments impacting its financial outlook and strategic direction ...

Medicare Part D plans usually cover the cost of antipsychotic drugs like Nuplazid. The cost depends on the drug’s tier in your insurance pan’s formulary.

Nuplazid (pimavanserin) is a brand-name medication that healthcare professionals often prescribe to help manage delusions or hallucinations with Parkinson’s disease. Prescription drug plans (PDP ...

Two recent studies indicate that Nuplazid (pimavanserin) is safe and tolerated well in older or frail adults who experience psychosis linked to Parkinson’s disease.

The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

Acadia’s first drug, Nuplazid, is the first and the only FDA-approved treatment for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis in the United ...